Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial
Ivarmacitinib demonstrated efficacy and good tolerability in treating moderate to severe AD with diverse patient characteristics.
Authors
- Aijun Chen (ORCID: https://orcid.org/0000-0002-2076-0555)
- Huibin Yin
- Suwei Tang
- Chaoying Gu (ORCID: https://orcid.org/0009-0009-9266-6785)
- Jinhua Xu
Institutions
- Tongji University (CN)
- Fudan University (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Shanghai Skin Disease Hospital (CN)
- Huashan Hospital (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1080/09546634.2025.2596524
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00